UY25404A1 - Parocedimiento para efectuar una cristalización a estado sólido de un compuesto orgánico molecular alotrópico en partículas de tamaño y formas definidos - Google Patents

Parocedimiento para efectuar una cristalización a estado sólido de un compuesto orgánico molecular alotrópico en partículas de tamaño y formas definidos

Info

Publication number
UY25404A1
UY25404A1 UY25404A UY25404A UY25404A1 UY 25404 A1 UY25404 A1 UY 25404A1 UY 25404 A UY25404 A UY 25404A UY 25404 A UY25404 A UY 25404A UY 25404 A1 UY25404 A1 UY 25404A1
Authority
UY
Uruguay
Prior art keywords
particles
allotropic
solid state
uniform
organic compounds
Prior art date
Application number
UY25404A
Other languages
English (en)
Inventor
Angeles Uribe Juan
De Gyves Aurelio
Abraham Gomez
Original Assignee
Skendi Finance Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21853984&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY25404(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Skendi Finance Ltd filed Critical Skendi Finance Ltd
Publication of UY25404A1 publication Critical patent/UY25404A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2989—Microcapsule with solid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)

Abstract

Partículas de configuración uniforme estables para almacenamiento, caracterizadas porque comprenden al menos dos compuestos orgánicos alotrópicos (particularmente un hidrato, esteroide o un esterol, y/o uno de dichos compuestos orgánicos se selecciona de oxatomida, nifedipina, astemizol y cisaprida), cada uno de los cuales consiste de un carácter cristalino uniforme y una pluralidad de dominios cristalino, siendo la estabilidad de dichas partículas, en almacenaje en medio acuoso con retención de su configuración uniforme de al menos un mes. Especialmente se puntualiza que el esteroide o esterol sea seleccionado del grupo 17-beta-estradiol, estrógeno, testosterona, progesterona, colesterol y mezclas de los mismos. Formas preferidas para tales partículas son microesferas, particularmente aquellas con diámetros comprendidos entre 1 y 1000 micrones; donde dichas partículas conformadas estables son particularmente adecuadas para la fabricación de formulaciones farmacéuticas, en particular cuando se desea una liberación sostenida y una bio-disponibilidad uniforme. Las partículas están formadas por una cristalización a estado sólido de compuestos orgánicos alotrópicos según los descritos; por tanto se incluye un proceso que brinda un medio para obtener forma cristalina estable en almacenamiento de dicho compuesto alotrópico sin perdida ni deterioro de las dimensiones de las partículas originales.
UY25404A 1998-02-25 1999-02-24 Parocedimiento para efectuar una cristalización a estado sólido de un compuesto orgánico molecular alotrópico en partículas de tamaño y formas definidos UY25404A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/030,388 US6287693B1 (en) 1998-02-25 1998-02-25 Stable shaped particles of crystalline organic compounds

Publications (1)

Publication Number Publication Date
UY25404A1 true UY25404A1 (es) 1999-05-14

Family

ID=21853984

Family Applications (1)

Application Number Title Priority Date Filing Date
UY25404A UY25404A1 (es) 1998-02-25 1999-02-24 Parocedimiento para efectuar una cristalización a estado sólido de un compuesto orgánico molecular alotrópico en partículas de tamaño y formas definidos

Country Status (35)

Country Link
US (7) US6287693B1 (es)
EP (4) EP2085075B1 (es)
JP (2) JP4885357B2 (es)
KR (1) KR100726315B1 (es)
CN (2) CN1146407C (es)
AR (3) AR018107A1 (es)
AT (2) ATE427102T1 (es)
AU (1) AU747779B2 (es)
BR (1) BR9908156A (es)
CA (1) CA2319176C (es)
CL (1) CL2010001333A1 (es)
CY (1) CY1118522T1 (es)
CZ (1) CZ301042B6 (es)
DE (2) DE69940684D1 (es)
DK (3) DK1772141T3 (es)
EE (1) EE05019B1 (es)
ES (3) ES2324366T3 (es)
HK (2) HK1036017A1 (es)
HU (1) HUP0101271A3 (es)
ID (1) ID26523A (es)
IL (2) IL137970A0 (es)
MY (1) MY138375A (es)
NO (1) NO331804B1 (es)
NZ (1) NZ505987A (es)
PE (1) PE20000393A1 (es)
PL (1) PL196369B1 (es)
PT (1) PT2085075T (es)
RU (1) RU2225708C2 (es)
SA (1) SA99200098B1 (es)
TR (1) TR200002462T2 (es)
TW (1) TWI256308B (es)
UA (1) UA73470C2 (es)
UY (1) UY25404A1 (es)
WO (1) WO1999043304A1 (es)
ZA (1) ZA991058B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6287693B1 (en) 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
LT2767539T (lt) 2002-05-16 2017-09-25 Janssen Sciences Ireland Uc Pseudopolimorfinės živ proteazės inhibitorių formos
US20040028747A1 (en) * 2002-08-06 2004-02-12 Tucker Christopher J. Crystalline drug particles prepared using a controlled precipitation process
US20040028746A1 (en) * 2002-08-06 2004-02-12 Sonke Svenson Crystalline drug particles prepared using a controlled precipitation (recrystallization) process
DK1844765T3 (en) * 2003-06-13 2015-04-27 Skendi Finance Ltd Slow release estradiol progesterone formulation
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
CA2532874A1 (en) * 2003-07-22 2005-02-03 Baxter International Inc. Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof
ATE399536T1 (de) * 2003-12-04 2008-07-15 Pfizer Prod Inc Verfahren zur herstellung von pharmazeutischen multiteilchenförmigen produkten
HUE030128T2 (en) 2004-02-23 2017-04-28 Euro Celtique Sa Anti-abuse device for transdermal opioid administration
RU2008100543A (ru) * 2005-06-17 2009-07-27 БАСФ Акциенгезельшафт (DE) Способ получения усилителей эффекта отбеливания
MX2010010512A (es) * 2008-03-26 2010-11-09 Alltranz Inc Formulaciones transdermicas de agonistas y antagonistas-agonistas de opiato que impiden el abuso.
EP2272519A4 (en) * 2008-04-14 2011-04-27 Posi Visionary Solutions Llp METHOD AND PHARMACEUTICAL COMPOSITION FOR ACHIEVING THE PLASMA PROGESTERONE MIRRORS NECESSARY FOR VARIOUS THERAPEUTIC INDICATIONS
FR2939326B1 (fr) * 2008-12-10 2011-04-01 Univ Joseph Fourier Procede et dispositif de controle d'une cristallisation.
EP2477610A1 (en) 2009-09-17 2012-07-25 Upsher-Smith Laboratories, Inc. A sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti -inflammatory drug
UY33103A (es) * 2009-12-15 2011-07-29 Techsphere S A De C V Formulacion farmaceutica parenteral en suspension, de liberacion sostenida, en dosis baja y ultra baja, en terapia hormonal en el sindrome climaterico
WO2011115066A1 (ja) * 2010-03-19 2011-09-22 第一三共株式会社 ジアミン誘導体の結晶およびその製造方法
US9351924B2 (en) 2011-03-11 2016-05-31 Snu R&Db Foundation Drug delivery system including laminated structure
KR101314126B1 (ko) 2011-03-11 2013-10-04 서울대학교산학협력단 다면체 형상의 약물 전달 시스템
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
HUE055562T2 (hu) 2011-11-23 2021-11-29 Therapeuticsmd Inc Természetes kombinációjú hormon helyettesítõ kiszerelések, és terápiák ezekkel
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
UA119848C2 (uk) 2013-03-15 2019-08-27 Інсайт Холдинґс Корпорейшн Трициклічні гетероцикли як інгібітори білків бет
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
LT3134403T (lt) 2014-04-23 2020-05-11 Incyte Corporation 1h-pirolo[2,3-c]piridin-7(6h)-onai ir pirazolo[3,4-c]piridin-7(6h)-onai, kaip bet baltymų inhibitoriai
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
ITUB20153652A1 (it) 2015-09-16 2017-03-16 Fatro Spa Microsfere contenenti lattoni macrociclici antielminitici
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
EP3472157B1 (en) 2016-06-20 2023-04-12 Incyte Corporation Crystalline solid forms of a bet inhibitor
PL236889B1 (pl) * 2017-10-03 2021-02-22 Univ Warszawski Medyczny Nowa forma krystaliczna bezwodnego 17-β-estradiolu, sposób jej otrzymywania oraz kompozycja farmaceutyczna zawierająca nową formę krystaliczną bezwodnego 17-β-estradiolu i jej zastosowanie
EP3542786A1 (en) * 2018-03-21 2019-09-25 ITF Research Pharma, S.L.U. Progesterone intravaginal devices
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2447362A (en) 1945-11-01 1948-08-17 Rca Corp Production of crystals
US3800038A (en) * 1972-04-21 1974-03-26 Biolog Concepts Inc Uterine administraton of eutectic solid solutions of steroid hormones in a steroidal lipid carrier
US4230621A (en) * 1978-05-01 1980-10-28 E. R. Squibb & Sons, Inc. Steroid derivatives and their use in radioimmunoassays
DE2843963A1 (de) * 1978-10-09 1980-04-24 Merck Patent Gmbh Im koerper resorbierbare geformte masse auf basis von kollagen und ihre verwendung in der medizin
IL63968A (en) 1980-10-01 1985-10-31 Glaxo Group Ltd Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
JPS5799562A (en) 1980-12-12 1982-06-21 Nippon Shinyaku Co Ltd Preparation of microcrystal
DE3049196A1 (de) 1980-12-24 1982-07-29 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von granulaten aus organischen in form einer schmelze vorliegenden stoffen
US4447426A (en) * 1982-01-18 1984-05-08 E. R. Squibb & Sons, Inc. Steroid monohydrates, formulations containing same and method
JPS58143832A (ja) 1982-02-22 1983-08-26 Yoshiaki Kawashima 結晶性化学物質の球状化再結晶法
DE3213025C2 (de) 1982-04-02 1997-06-12 Fischer Karl Ind Gmbh Verfahren zur Nachkondensation von Polykondensaten
GB8618847D0 (en) * 1986-08-01 1986-09-10 Smith Kline French Lab Pharmaceutical formulations
JPH0714625B2 (ja) 1987-03-30 1995-02-22 呉羽化学工業株式会社 高結晶化ポリアリ−レンチオエ−テル成形物
US4897307A (en) 1987-08-11 1990-01-30 The Dow Chemical Company Process for the solvent-induced crystallization of amorphous poly(etheretherketone)-type polymers and the article formed thereby
US4948871A (en) 1987-09-28 1990-08-14 Asahi Kasei Kogyo Kabushiki Kaisha Method for producing a crystallized aromatic polycarbonate, and a crystallized aromatic polycarbonate obtained thereby
US4919899A (en) 1988-02-29 1990-04-24 Herrmann Frederick T Crystal growth apparatus
YU120988A (en) * 1988-06-23 1990-06-30 Lek Tovarna Farmacevtskih Process for preparing new dispersion pills of cimetidine
IT1230566B (it) 1988-10-17 1991-10-28 Vectorpharma Int Farmaci poco solubili supportati su sostanze polimeriche in forma atta all'aumento della velocita' di dissoluzione
US5360478A (en) 1989-10-16 1994-11-01 Phasex Corporation Gas anti-solvent recrystallization process
FR2663223B1 (fr) * 1990-06-14 1994-12-02 Af Aplicaciones Far Lab Forme galenique parenterale.
FR2663224B1 (fr) * 1990-06-14 1995-01-20 Applicationes Farmaceuticas Sa Forme galenique parenterale.
JPH04305226A (ja) 1991-01-25 1992-10-28 Senichi Masuda ガス中窒素酸化物の低減方法
SE9101090D0 (sv) 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble substances
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
US5391810A (en) 1991-05-23 1995-02-21 Ajinomoto Co., Inc. Method of crystallizing α-L-aspartyl-L-phenylalanine methyl ester
DE4130173A1 (de) 1991-09-11 1993-03-18 Bayer Ag Pharmazeutische zubereitungen mit einer speziellen kristallmodifikation des 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridindicarbonsaeure-isopropyl-(2-methoxyethyl)-esters
DE4218929C1 (es) 1992-06-10 1993-09-09 Deutsche Bundesbahn, Vertreten Durch Das Bundesbahn-Zentralamt Minden (Westf.), 4950 Minden, De
US5290913A (en) 1992-10-08 1994-03-01 Carrier Vibrating Equipment, Inc. Method and apparatus for the heat treatment of material
US5558678A (en) 1992-11-13 1996-09-24 Karl Fischer Industrieanlagen Gmbh Process and apparatus for continuous crystallization of plastic granules
US5643595A (en) 1992-11-24 1997-07-01 Alkermes Controlled Therapeutics Inc. Ii Growth promoters for animals
WO1994020116A1 (en) * 1993-03-10 1994-09-15 University Of Alabama Research Foundation Artificial primers for glycogen synthesis
US5409605A (en) * 1993-08-05 1995-04-25 Chemical Lime Company Apparatus and method for treating waste sludge
JPH0757558A (ja) * 1993-08-09 1995-03-03 Showa Electric Wire & Cable Co Ltd 耐熱絶縁電線
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US5849651A (en) * 1995-06-01 1998-12-15 Kabushiki Kaisha Toshiba Reversible thermal recording medium
JPH0957558A (ja) * 1995-08-18 1997-03-04 Nabeya Iron & Tool Works Ltd スライド装置
JPH09227558A (ja) * 1996-02-28 1997-09-02 Fujisawa Pharmaceut Co Ltd チアゾール化合物の安定な結晶およびその製造方法
US6287693B1 (en) 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
JP2000143832A (ja) 1998-11-10 2000-05-26 Toppan Printing Co Ltd 高剛性を有するフィルムまたはシート

Also Published As

Publication number Publication date
PE20000393A1 (es) 2000-05-04
NZ505987A (en) 2003-07-25
US20020168395A1 (en) 2002-11-14
EP1056444A1 (en) 2000-12-06
EP2085075B1 (en) 2016-09-28
HK1155384A1 (en) 2012-05-18
DK2085075T3 (en) 2017-01-23
JP2002504507A (ja) 2002-02-12
IL137970A (en) 2006-10-05
CL2010001333A1 (es) 2011-04-25
ATE345779T1 (de) 2006-12-15
MY138375A (en) 2009-05-29
US6663895B2 (en) 2003-12-16
EP2319497A1 (en) 2011-05-11
AR018107A1 (es) 2001-10-31
ES2275334T3 (es) 2007-06-01
DK1056444T3 (da) 2007-03-12
AU2293699A (en) 1999-09-15
US20030191101A1 (en) 2003-10-09
CN1291887A (zh) 2001-04-18
CZ20003047A3 (cs) 2000-11-15
NO20004241L (no) 2000-08-24
KR20010034540A (ko) 2001-04-25
US6287693B1 (en) 2001-09-11
AR077167A2 (es) 2011-08-10
HUP0101271A3 (en) 2002-10-28
ES2609284T3 (es) 2017-04-19
EE200000492A (et) 2002-02-15
AU747779B2 (en) 2002-05-23
ES2324366T3 (es) 2009-08-05
DK1772141T3 (da) 2009-07-20
IL137970A0 (en) 2001-10-31
DE69940684D1 (de) 2009-05-14
ZA991058B (en) 1999-08-11
KR100726315B1 (ko) 2007-06-11
PL343170A1 (en) 2001-07-30
HK1036017A1 (en) 2001-12-21
RU2225708C2 (ru) 2004-03-20
EE05019B1 (et) 2008-06-16
CA2319176C (en) 2007-09-11
NO20004241D0 (no) 2000-08-24
CN1524608A (zh) 2004-09-01
DE69934099T2 (de) 2007-06-21
CN1146407C (zh) 2004-04-21
US6638536B2 (en) 2003-10-28
AR077168A2 (es) 2011-08-10
TWI256308B (en) 2006-06-11
CN100528140C (zh) 2009-08-19
US20040166164A1 (en) 2004-08-26
UA73470C2 (uk) 2005-08-15
JP2011241220A (ja) 2011-12-01
US7427413B2 (en) 2008-09-23
HUP0101271A2 (hu) 2001-09-28
EP1772141B1 (en) 2009-04-01
CZ301042B6 (cs) 2009-10-21
WO1999043304A1 (en) 1999-09-02
US6737081B2 (en) 2004-05-18
SA99200098B1 (ar) 2006-04-26
PT2085075T (pt) 2017-01-04
DE69934099D1 (de) 2007-01-04
JP4885357B2 (ja) 2012-02-29
NO331804B1 (no) 2012-04-10
US6528094B1 (en) 2003-03-04
ID26523A (id) 2001-01-11
BR9908156A (pt) 2000-10-31
US6537580B1 (en) 2003-03-25
EP2085075A1 (en) 2009-08-05
EP1056444B1 (en) 2006-11-22
US20030147964A1 (en) 2003-08-07
EP1772141A1 (en) 2007-04-11
ATE427102T1 (de) 2009-04-15
EP2319497B1 (en) 2012-08-22
PL196369B1 (pl) 2007-12-31
CA2319176A1 (en) 1999-09-02
CY1118522T1 (el) 2017-07-12
TR200002462T2 (tr) 2000-11-21

Similar Documents

Publication Publication Date Title
UY25404A1 (es) Parocedimiento para efectuar una cristalización a estado sólido de un compuesto orgánico molecular alotrópico en partículas de tamaño y formas definidos
RU2000124327A (ru) Стабильные частицы определенной формы кристаллических органических соединений
JP2002504507A5 (es)
ES524518A0 (es) Un procedimiento para preparar un agente anti-inflamatorio
Tritschler et al. Controlling the selective formation of calcium sulfate polymorphs at room temperature
HUP0001547A2 (hu) Az S-omeprazol új formája
BR0203148A (pt) Composição quìmica de liberação controlada biodegradável e método para preparar a mesma
MY118718A (en) Crystalline macrolides and process for their preparation
Iglič et al. Possible role of phospholipid nanotubes in directed transport of membrane vesicles
Wantha et al. Influence of Solvents on Solution‐Mediated Polymorphic Transformation of the Polymorphs of L‐Histidine
HUP0004657A2 (hu) Eljárás cukrok kristályosítására
WO2003018188A1 (fr) Systeme de solvant multiphase compatible
MY125975A (en) Crystalline form vii of cabergoline
Wang et al. The curious case of exploding quantum dots: anomalous migration and growth behaviors of Ge under Si oxidation
WO2003033462A3 (en) Systems and methods for the generation of crystalline polymorphs
Anderson et al. A cytological analysis of fertilization in Chaetopterus pergamentaceus
DE60134469D1 (de) Humane epitheliale zellen von müllerian ductus-abstammende, verfahren zur ihrer isolierung und verwendungen davon
PE20010917A1 (es) Forma cristalina de eplerenona que muestra un aumento en la velocidad de disolucion
de Villiers et al. Comparison of the physical and chemical stability of niclosamide crystal forms in aqueous versus nonaqueous suspensions
Sivakumar et al. Homochiral crystal generation via sequential dehydration and Viedma ripening
CO4970800A1 (es) Forma termodinamicamente estable del acido (r)-3(((4-fluoro- fenil) sulfonil)amino)-1,2,3,4-tetrahidro-9h-carbazo-9-pro- panoico (ramatroban)
HUP0300734A2 (hu) Biztosíték és eljárás annak elżállítására, valamint forraszanyag
Zheng et al. Weaving colloidal webs around droplets: spontaneous assembly of extended colloidal networks encasing microfluidic droplet ensembles
Brittain X-ray diffraction II: using single-crystal X-ray diffraction to study polymorphism and solvatomorphism
BR0017102A (pt) Agente de liberação, e, método para formar materiais lignocelulósicos ligados com aglutinante de poliisocianato orgânico

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20160912